ArticleCardio-oncology (London, England)2026
Cardiovascular event burden in women with breast cancer treated with CDK4/6 inhibitors: a retrospective matched cohort study.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclin-dependent kinase (CDK) 4/6 inhibitors improve outcomes in hormone receptor-positive, HER2-negative breast cancer, but real-world data on cardiovascular (CV) toxicity are limited.
methodsIn this single-centre retrospective matched cohort study, women with breast cancer treated with a CDK4/6 inhibitor at University Hospitals Leuven between 2016 and 2022 constituted the index cohort. Age- and BMI-matched women without active cancer, selected from the population-based FLEMENGHO study, constituted the reference cohort. CV events were identified from medical records, and follow-up in the reference cohort was truncated to the maximum follow-up duration of the index cohort to improve comparability.
resultsAmong 536 matched pairs, the index cohort had a significantly higher observed incidence of CV events than the reference cohort (67.7 vs 17.2 per 1,000 person-years; P < 0.0001), including the cardiac composite (28.0 vs 9.6 per 1,000 person-years; P < 0.0001). Venous thromboembolism (11.6% vs 0.75%) and atrial fibrillation/flutter (4.7% vs 1.5%) were more frequent in the index cohort. Coronary events, stroke, and heart failure did not differ significantly. After adjustment for measured baseline CV risk factors, index-cohort membership remained associated with higher risks of CV events (HR, 3.63; 95% CI, 2.57-5.13) and cardiac events (HR, 3.25; 95% CI, 1.97-5.35).
conclusionsWomen with breast cancer receiving CDK4/6 inhibitors had a substantially higher observed burden of venous thromboembolism and atrial arrhythmias than the age- and BMI-matched population reference cohort without active cancer. These findings support cardiovascular awareness in this population. However, the comparison cannot isolate a drug-specific effect because active malignancy, previous cancer therapies, baseline differences, and surveillance intensity may also contribute.
trial registrationThis retrospective single-centre matched cohort study was approved by the Ethics Committee UZ/KU Leuven (approval numbers s68763 and s64406). As a retrospective observational study, prospective trial registration was not required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.